EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyse

Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Johann Bill Pinedo-Avila iD, Jessica Lucia Valera-Cabrera iD, Ana Avalos-Rodríguez, Sarita M Fernández-Poma iD, Carlos Enrique Martínez Castro iD, Renzo G Cañote, Karina Chocce, Alvaro Taype-Rondan iD, David R Soriano-Moreno iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70155 ↗

At a glance

Systematische Übersicht in Catheterization and Cardiovascular Interventions, 2025. Written by Johann Bill Pinedo-Avila and 8 co-authors. Institution: Unidad de Cuidados Intensivos de Neurocirugía del Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru. Major MEDLINE topics: Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. 28 references. Funded by: This study was self-funded by the authors..

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Current guidelines recommend clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI), yet the comparative benefits are unclear.

Aims

The aim of this study was to evaluate the efficacy and safety of ticagrelor versus clopidogrel in patients with CCS undergoing PCI.

Methods

We searched PubMed/MEDLINE, EMBASE, CENTRAL databases from inception to February 15, 2025. We included parallel randomized controlled trials (RCTs) involving adults with CCS undergoing PCI, where the intervention group received ticagrelor as maintenance therapy and the control group received clopidogrel. Primary outcomes included all‐cause or cardiovascular mortality, myocardial infarction, quality of life, heart failure, stroke/transient ischemic attack (TIA), revascularization, and adverse events. Study selection and data extraction were conducted independently. We determined the certainty of evidence using the GRADE approach.

Results

We included nine RCTs, with 3370 patients. Compared to clopidogrel, ticagrelor probably results in no important difference in cardiovascular mortality and hospital stay; may not have an important effect on stroke and/or TIA; and may not have an important effect on all‐cause mortality, heart failure, and revascularization, but the evidence is very uncertain. Additionally, the evidence is very uncertain about the effect on myocardial infarction. Regarding safety outcomes, ticagrelor probably results in no important difference in major bleeding, minor bleeding, any bleeding, or dyspnea. However, it probably increases the risk of chest pain/tightness ( + 7.5 per 100; 95% CI: +1.4 to +21.7).

Conclusion

In patients with CCS undergoing PCI, ticagrelor probably has a similar efficacy and safety to clopidogrel in most cardiovascular outcomes. However, it probably increases the risk of chest pain/tightness.

Subjects

MeSH terms (MEDLINE)

TicagrelorClopidogrelPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsCoronary Artery DiseaseHumansTreatment OutcomeRisk FactorsRisk AssessmentRandomized Controlled Trials as TopicMaleFemaleMiddle AgedAgedChronic DiseaseTime FactorsHemorrhage

Author keywords

angioplasty, balloon, coronarychronic coronary syndromeclopidogrelcoronary artery diseaseplatelet aggregation inhibitorsticagrelor

Substances

TicagrelorClopidogrelPlatelet Aggregation Inhibitors

Authors and institutions

  • Unidad de Cuidados Intensivos de Neurocirugía del Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
  • Universidad Peruana de Ciencias Aplicadas, Lima, Peru.
  • Universidad San Martín de Porres, Lima, Peru.
  • Universidad Nacional Federico Villarreal, Lima, Peru.
  • Universidad Privada Antenor Orrego (UPAO), Trujillo, Peru.
  • Oftalmosalud, Lima, Peru.

ORCID profiles: Johann Bill Pinedo-Avila, Jessica Lucia Valera-Cabrera, Sarita M Fernández-Poma, Carlos Enrique Martínez Castro, Alvaro Taype-Rondan, David R Soriano-Moreno

Funding

  • This study was self-funded by the authors.

Cite

APA

Pinedo-Avila, J. B., Valera-Cabrera, J. L., Avalos-Rodríguez, A., Fernández-Poma, S. M., Castro, C. E. M., Cañote, R. G., Chocce, K., Taype-Rondan, A., & Soriano-Moreno, D. R. (2025). Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70155

Vancouver

Pinedo-Avila JB, Valera-Cabrera JL, Avalos-Rodríguez A, Fernández-Poma SM, Castro CEM, Cañote RG, et al. Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70155

BibTeX
@article{PinedoAvila2025,
  author = {Pinedo-Avila, Johann Bill and Valera-Cabrera, Jessica Lucia and Avalos-Rodríguez, Ana and Fernández-Poma, Sarita M and Castro, Carlos Enrique Martínez and Cañote, Renzo G and Chocce, Karina and Taype-Rondan, Alvaro and Soriano-Moreno, David R},
  title = {Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70155}
}
Start for free →